Glanbia Nutritionals, in partnership with Jellice Co., has launched Collameta, a patented high-potency collagen tripeptide that is clinically evidenced to be absorbed four-times faster and have greater efficacy in vivo than competing collagen peptide products.
 
“We are excited to bring Collameta to market because it provides a much higher percentage of bioactive tripeptide than other tripeptides on the market,” said Rachel Schreck, associate strategic product manager at Glanbia Nutritionals.
 
Collameta will initially be offered in North America. “Formulating with collagen has been a challenge because standard collagen peptides are too big to be absorbed directly, resulting in a larger dose and limitations on certain applications,” Schreck said. “Collameta is a unique collagen tripeptide with a small molecular weight and high potency allowing for a much smaller dose, just one-tenth of a traditional collagen peptide dose, reducing overage issues and making it possible to add it to a wide variety of applications including ready-to-drink beverages, powder drink mixes, gummies, tablets, capsules, gels and bars.”
 
Collameta’s unique attributes include its low molecular weight of about 300 Daltons, allowing it to be absorbed into the bloodstream four times more quickly than traditional collagen peptides. It contains a higher percentage (50%) of bioactive peptides than other tripeptides on the market (15%) and traditional collagen peptides (2%). Only a small dose of about 500-1,000 mg is required daily, allowing for effective inclusion in a wide variety of applications. Tripeptides help to trigger the endogenous production of collagen needed to support skin, bones, and joints.